Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $74.44.

Several research analysts have commented on the company. JonesTrading raised their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Barclays began coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective for the company. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. The Goldman Sachs Group upped their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th.

Insider Activity

In other news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the completion of the sale, the director directly owned 13,000 shares of the company’s stock, valued at approximately $606,710. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mika Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the transaction, the director directly owned 87,373 shares in the company, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 189,849 shares of company stock worth $11,140,085. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of large investors have recently made changes to their positions in the stock. KBC Group NV purchased a new stake in Enliven Therapeutics in the 1st quarter worth approximately $38,000. State of Wyoming acquired a new position in shares of Enliven Therapeutics during the second quarter worth approximately $96,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth approximately $126,000. WINTON GROUP Ltd acquired a new position in Enliven Therapeutics during the second quarter worth $228,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $259,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

ELVN opened at $40.63 on Friday. The company has a fifty day moving average of $54.36 and a 200 day moving average of $47.78. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -24.33 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics will post -1.75 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.